Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer

3,95 valoración promedio
( 113 valoraciones por Goodreads )
 
9780812991840: Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free.

        Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers.

        Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.
From the Hardcover edition.

"Sinopsis" puede pertenecer a otra edición de este libro.

Review:

Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer reads like a novel at first. Oncologist Dennis Slamon has spent 13 years "obsessed with a molecule called Her-2," which he believed "held the key to nothing less than curing breast cancer." The book chronicles the search to unlock the secrets of Her-2/neu, a protein that makes cancer cells grow quickly; the discovery of the Her-2/neu antibody, which resulted in tumors shrinking and, sometimes, remission of the cancer; and the development of the drug Herceptin. It is also the story of the women with breast cancer who participated in Herceptin's clinical trials, including Anne McNamara, who has been fighting tumor after tumor since 1978.

The scientific and research-history sections are heavy and slow going, but Robert Bazell effectively juxtaposes the difficult scientific concepts and long research history of Her-2 with human drama. He keeps bringing the reader back to the threads of the personal stories we are following--especially the women with breast cancer and their determination to recapture their health. This is what makes Her-2 so compelling. --Joan Price

From the Back Cover:

"A fascinating description of the people and politics behind the development of a new breast cancer treatment. With Her-2 we are finally seeing the fulfillment of research's promise to move us behind slash, burn, and poison toward a more targeted approach to this devastating disease."--Susan Love, M.D., author of Dr. Susan Love's Breast Book

"Sobre este título" puede pertenecer a otra edición de este libro.

Los mejores resultados en AbeBooks

1.

Bazell, Robert
Editorial: Random House Inc (1998)
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos Cantidad: > 20
Librería
Paperbackshop-US
(Wood Dale, IL, Estados Unidos de America)
Valoración
[?]

Descripción Random House Inc, 1998. PAP. Estado de conservación: New. New Book. Shipped from US within 10 to 14 business days. Established seller since 2000. Nº de ref. de la librería VR-9780812991840

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 6,76
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 3,39
A Estados Unidos de America
Destinos, gastos y plazos de envío

2.

BAZELL, ROBERT
Editorial: Penguin Random House
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos Cantidad: > 20
Librería
INDOO
(Avenel, NJ, Estados Unidos de America)
Valoración
[?]

Descripción Penguin Random House. Estado de conservación: New. Brand New. Nº de ref. de la librería 0812991842

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 7,64
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 2,98
A Estados Unidos de America
Destinos, gastos y plazos de envío

3.

Robert Bazell
Editorial: Random House USA Inc, United States (1998)
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos Paperback Cantidad: 1
Librería
The Book Depository
(London, Reino Unido)
Valoración
[?]

Descripción Random House USA Inc, United States, 1998. Paperback. Estado de conservación: New. Language: English . Brand New Book. Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield s aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech s clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn t otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient s bedside. Bazell s deft portraits introduce us to the remarkable people instrumental in Herceptin s history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon s research; and Marti Nelson, who inspired the activists who lobbied for a compassionate use program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science. From the Hardcover edition. Nº de ref. de la librería AAS9780812991840

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 10,95
Convertir moneda

Añadir al carrito

Gastos de envío: GRATIS
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

4.

Robert Bazell
Editorial: Random House USA Inc, United States (1998)
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos Paperback Cantidad: 10
Librería
Book Depository hard to find
(London, Reino Unido)
Valoración
[?]

Descripción Random House USA Inc, United States, 1998. Paperback. Estado de conservación: New. Language: English . This book usually ship within 10-15 business days and we will endeavor to dispatch orders quicker than this where possible. Brand New Book. Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield s aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech s clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn t otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient s bedside. Bazell s deft portraits introduce us to the remarkable people instrumental in Herceptin s history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon s research; and Marti Nelson, who inspired the activists who lobbied for a compassionate use program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science. From the Hardcover edition. Nº de ref. de la librería BTE9780812991840

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 10,95
Convertir moneda

Añadir al carrito

Gastos de envío: GRATIS
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

5.

Robert Bazell
Editorial: Random House USA Inc, United States (1998)
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos Paperback Cantidad: 1
Librería
The Book Depository US
(London, Reino Unido)
Valoración
[?]

Descripción Random House USA Inc, United States, 1998. Paperback. Estado de conservación: New. Language: English . Brand New Book. Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield s aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech s clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn t otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient s bedside. Bazell s deft portraits introduce us to the remarkable people instrumental in Herceptin s history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon s research; and Marti Nelson, who inspired the activists who lobbied for a compassionate use program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science. From the Hardcover edition. Nº de ref. de la librería AAS9780812991840

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 11,41
Convertir moneda

Añadir al carrito

Gastos de envío: GRATIS
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

6.

Bazell, Robert
Editorial: Random House
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos PAPERBACK Cantidad: > 20
Librería
Mediaoutlet12345
(Springfield, VA, Estados Unidos de America)
Valoración
[?]

Descripción Random House. PAPERBACK. Estado de conservación: New. 0812991842 *BRAND NEW* Ships Same Day or Next!. Nº de ref. de la librería SWATI2132246423

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 9,16
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 3,39
A Estados Unidos de America
Destinos, gastos y plazos de envío

7.

Robert Bazell
Editorial: Random House Inc (1998)
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos Tapa blanda Cantidad: 5
Librería
Valoración
[?]

Descripción Random House Inc, 1998. Estado de conservación: New. Nº de ref. de la librería TV9780812991840

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 12,40
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 2,99
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío

8.

Robert Bazell, Mary-Claire King
Editorial: Random House USA Inc
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos Paperback / softback Cantidad: 1
Librería
THE SAINT BOOKSTORE
(Southport, Reino Unido)
Valoración
[?]

Descripción Random House USA Inc. Paperback / softback. Estado de conservación: new. BRAND NEW, Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer, Robert Bazell, Mary-Claire King, Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science. "From the Hardcover edition.". Nº de ref. de la librería B9780812991840

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 7,79
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 7,79
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

9.

Robert Bazell
Editorial: Random House Publishing Group 1998-08-25, New York (1998)
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos paperback Cantidad: 1
Librería
Blackwell's
(Oxford, OX, Reino Unido)
Valoración
[?]

Descripción Random House Publishing Group 1998-08-25, New York, 1998. paperback. Estado de conservación: New. Nº de ref. de la librería 9780812991840

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 11,55
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 6,73
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

10.

Robert Bazell
Editorial: Random House Inc (1998)
ISBN 10: 0812991842 ISBN 13: 9780812991840
Nuevos Paperback Cantidad: 2
Librería
Revaluation Books
(Exeter, Reino Unido)
Valoración
[?]

Descripción Random House Inc, 1998. Paperback. Estado de conservación: Brand New. 1st edition. 240 pages. 8.75x6.00x0.50 inches. In Stock. Nº de ref. de la librería z-0812991842

Más información sobre esta librería | Hacer una pregunta a la librería

Comprar nuevo
EUR 13,02
Convertir moneda

Añadir al carrito

Gastos de envío: EUR 6,73
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío

Existen otras copia(s) de este libro

Ver todos los resultados de su búsqueda